Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Oncology
  4. microRNA-26a-5p Promotes Proliferation and Migration of Osteosarcoma Cells by Targeting HOXA5 in vitro and in vivo

microRNA-26a-5p Promotes Proliferation and Migration of Osteosarcoma Cells by Targeting HOXA5 in vitro and in vivo

OncoTargets and Therapy, 2019 · DOI: http://doi.org/10.2147/OTT.S232100 · Published: December 1, 2019

OncologyGenetics

Simple Explanation

This study investigates the role of miR-26a-5p in osteosarcoma cells. The researchers found that miR-26a-5p is highly expressed in osteosarcoma cell lines compared to noncancerous cells. This suggests that miR-26a-5p might be involved in the progression of osteosarcoma. The study further shows that overexpression of miR-26a-5p promotes cell proliferation and migration, but inhibits cell apoptosis. Conversely, reducing miR-26a-5p expression has the opposite effects. This indicates that miR-26a-5p promotes cell proliferation, migration, but inhibit apoptosis of U2OS. Researchers found that miR-26a-5p directly targets HOXA5 in U2OS cells. Overexpression of HOXA5 reversed the effects of miR-26a-5p on cell proliferation, migration, and apoptosis. These findings suggest that miR-26a-5p promotes proliferation and migration, but inhibits apoptosis of osteosarcoma cells by targeting HOXA5.

Study Duration
Not specified
Participants
Human MSCs, osteosarcoma cell lines (U2OS, Saos-2, and MG63), fibroblast cell line HFF-1, and osteoblast cell line hFOB1.19, nude mice
Evidence Level
In vitro and in vivo study

Key Findings

  • 1
    miR-26a-5p is highly expressed in osteosarcoma cell lines compared to noncancerous cells, especially in U2OS cells.
  • 2
    Overexpression of miR-26a-5p promotes cell proliferation, cell cycle progression, and migration, while inhibiting apoptosis in U2OS cells; conversely, downregulation of miR-26a-5p exhibits opposite effects.
  • 3
    miR-26a-5p directly targets HOXA5 in U2OS cells, and overexpression of HOXA5 reverses the effects of miR-26a-5p on cell proliferation, migration, and apoptosis; knockdown of miR-26a-5p or overexpression of HOXA5 increases cell sensitivity to paclitaxel.

Research Summary

This study investigates the role of miR-26a-5p in osteosarcoma cells and finds that it is highly expressed in osteosarcoma cell lines compared to noncancerous cells, suggesting its involvement in osteosarcoma progression. The study demonstrates that miR-26a-5p promotes cell proliferation, migration, and inhibits apoptosis in U2OS cells, indicating a positive correlation with carcinoma. It also identifies HOXA5 as a direct target of miR-26a-5p in U2OS cells, which affects cell proliferation, migration, and apoptosis. The research shows that miR-26a-5p overexpression promotes tumorigenesis of osteosarcoma in vivo, while knockdown decreases proliferation. Additionally, down-regulation of miR-26a-5p increases paclitaxel-induced cell apoptosis, suggesting miR-26a-5p could be a therapeutic target to improve the sensitivity of osteosarcoma to paclitaxel.

Practical Implications

Therapeutic Target

miR-26a-5p could serve as a novel therapeutic target for osteosarcoma treatment.

Chemosensitivity Enhancement

Targeting miR-26a-5p may improve the sensitivity of osteosarcoma cells to chemotherapeutic drugs like paclitaxel.

Underlying mechanisms of osteosarcoma

Further exploration of the HOXA5 pathway may provide new insights into osteosarcoma development.

Study Limitations

  • 1
    The study primarily focuses on U2OS cells, further research is needed to validate these findings in other osteosarcoma cell lines.
  • 2
    The underlying mechanisms of HOXA5 in osteosarcoma development require more investigation.
  • 3
    Further research is needed to validate miR-26a-5p as a therapeutic target in clinical settings.

Your Feedback

Was this summary helpful?

Back to Oncology